Anocca is a drug and immunotherapy developer aiming to uncover the therapeutic potential of T-cell immunity.
Anocca has raised $36.9M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in May 2023.
Anocca's investors include European Investment Bank, AMF, Swedbank Robur, Mellby Gård AB, Ramsbury Invest AB.
Anocca is headquartered in Södertälje, Sweden.
Anocca is a drug and immunotherapy developer aiming to uncover the therapeutic potential of T-cell immunity.
Anocca is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Anocca — Funding & Investors." VCBacked, May 31, 2023, https://www.vcbacked.co/company/anocca. Accessed September 30, 2026.
VCBacked. (2023). Anocca — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/anocca
{{cite web |title=Anocca — Funding & Investors |url=https://www.vcbacked.co/company/anocca |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated